RT Journal Article
SR Electronic
T1 Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e229128
DO 10.1136/bcr-2018-229128
VO 12
IS 5
A1 Loh, Chee Hoou
A1 Herkes, Geoffrey
YR 2019
UL http://casereports.bmj.com/content/12/5/e229128.abstract
AB We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications.